Wolters Kluwer announces two senior executive appointments
Wolters Kluwer, a global leader in information, software, and services for professionals, today announced Atul Dubey as General Manager of its Finance, Risk and Regulatory Reporting (FRR) business, part of its Corporate Performance & ESG (CP & ESG) division. Suzanne Konstance will succeed Dubey as General Manager of Wolters Kluwer Legal & Regulatory U.S, part of the company’s Legal & Regulatory division, effective May 1.
Karen Abramson, CEO of Wolters Kluwer CP & ESG, commented: “Atul’s deep understanding of the financial regulatory and risk landscape will be critical strengths as he takes this global leadership role for Wolters Kluwer FRR, driving growth and relentless innovation for our clients.”
Wolters Kluwer FRR’s award-winning OneSumX suite of solutions support financial institutions through innovative technology that enables and empowers clients to stay compliant with everchanging regulatory requirements, manage uncertainty through financial risk management offerings and drive efficiency.
“Serving over 800 customers in 40 countries, OneSumX for FRR has a significant global role in the financial services ecosystem,” Dubey commented. “I look forward to working with Karen and the talented team to drive product enhancement and innovation, delivering value to our clients, partners and regulators.”
Dubey joined Wolters Kluwer in 2016 as Chief Strategy Officer, with a strong background in institutional banking, having held senior leadership roles at Citigroup, S&P Global and Booz Allen.
Martin O’Malley, CEO of Wolters Kluwer Legal & Regulatory: “I am grateful for Atul’s incisive leadership, which has seen our solutions, services and customers thrive during a period of unparalleled transformation for our industry. At the same time, I am excited to welcome Suzanne to our division. Her deep industry expertise, commitment to innovation and experience in creating vibrant team cultures will continue to push our U.S. business to new heights.”
Konstance held leadership positions in Wolters Kluwer for eight years, in which she built a strong track record in product management, strategy and go-to-market. She most recently served as Vice President & Segment Leader of Lien Solutions for the Wolters Kluwer Compliance Solutions business unit – a part of the company’s Financial & Corporate Compliance (FCC) division. She successfully engaged in launching AI-enabled products to transform the business while managing to achieve an above-market growth rate. Prior to joining Wolters Kluwer, Konstance held senior roles at Pitney Bowes, Citibank, and MetLife.
“By combining unparalleled domain expertise with the latest AI-driven technology, Wolters Kluwer Legal & Regulatory U.S. is uniquely positioned to help today’s legal professionals achieve measurable efficiencies and gain valuable insights,” Konstance said. “I am eager to begin collaborating with this dynamic team as we chart a path toward continued growth.”
Wolters Kluwer Legal & Regulatory U.S. is a leading provider of information, business intelligence, and regulatory and legal workflow solutions for legal, corporate, and compliance professionals across several industries. Legisway, Wolters Kluwer’s award-winning and all-in-one SaaS legal information and contract management solution for corporate legal departments, recently launched new AI-enhanced functionality, accelerating the contract review process by enabling legal departments to effortlessly query their contracts using advanced natural language processing.
For more information about Wolters Kluwer, please visit: www.wolterskluwer.com
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417358923/en/
Contact information
Media
Sarah Whybrow
Associate Director, External Communications
Corporate Performance & ESG
Wolters Kluwer
Mob: +44 7855 186713
sarah.whybrow@wolterskluwer.com
Frank Ready
Manager, External Communications
Legal & Regulatory
Wolters Kluwer
Office: 717-205-3647
Email: Frank.Ready@wolterskluwer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom